Evidence map›Paper›PMID 30374110›Full record

ArticleNature communications2018

6mer seed toxicity in tumor suppressive microRNAs.

Quan Q Gao, William E Putzbach, Andrea E Murmann, Siquan Chen, Aishe A Sarshad, Johannes M Peter, Elizabeth T Bartom, Markus Hafner, Marcus E Peter

Abstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cancer kill code extension.Molecular therapy. Nucleic acids · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. CD95/Fas ligand induced toxicity.Biochemical Society transactions · 2023
    Article
  12. Identification of potential target genes inNon-coding RNA research · 2022
    Article
  13. Article
  14. Article
  15. Article
  16. DISE/6mer seed toxicity-a powerful anti-cancer mechanism with implications for other diseases.Journal of experimental & clinical cancer research : CR · 2021
    Review
  17. Non-targeting control for MISSION shRNA library silencesMolecular therapy. Nucleic acids · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Quan Q GaoDepartment of Medicine, Division Hematology/Oncology, Northwestern University, Chicago, IL, 60611, USA.
William E PutzbachDepartment of Medicine, Division Hematology/Oncology, Northwestern University, Chicago, IL, 60611, USA.
Andrea E MurmannDepartment of Medicine, Division Hematology/Oncology, Northwestern University, Chicago, IL, 60611, USA.
Siquan ChenCellular Screening Center, Institute for Genomics & Systems Biology, The University of Chicago, Chicago, IL, 60637, USA.
Aishe A SarshadLaboratory of Muscle Stem Cells and Gene Regulation, NIAMS, NIH, Bethesda, MD, 20892, USA.
Johannes M PeterDigiPen Institute of Technology, Redmond, WA, 98052, USA.
Elizabeth T BartomDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, 60611, USA.ORCID http://orcid.org/0000-0002-5618-2582
Markus HafnerLaboratory of Muscle Stem Cells and Gene Regulation, NIAMS, NIH, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0002-4336-6518
Marcus E PeterDepartment of Medicine, Division Hematology/Oncology, Northwestern University, Chicago, IL, 60611, USA. m-peter@northwestern.edu.ORCID http://orcid.org/0000-0003-3216-036X

Funding

CARCINOGENESIS TRAINING PROGRAMT32CA009560 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Kathleen Janee Green · 1986 to 2026
$8.4M
DISE - a natural cancer surveillance mechanism - a new road to cancer therapyR35CA197450 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PETER, MARCUS E. · 2015 to 2021
$6.2M
The role of AU-rich element binding proteins in shaping target mRNA expressionZIAAR041200 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI HAFNER, MARKUS · 2014 to 2023
$5.1M
Bioinformatics Analysis of Next Generation Sequencing Data from Cancer CellsR50CA221848 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Elizabeth Thomas Bartom · 2017 to 2026
$1.8M
NCI NIH HHS R35 CA197450NCI NIH HHS R50 CA221848NCI NIH HHS T32 CA009560Office of Extramural Research, National Institutes of Health (OER) R35CA197450
6 · The paper itself

Abstract

Many small-interfering (si)RNAs are toxic to cancer cells through a 6mer seed sequence (positions 2-7 of the guide strand). Here we performed an siRNA screen with all 4096 6mer seeds revealing a preference for guanine in positions 1 and 2 and a high overall G or C content in the seed of the most toxic siRNAs for four tested human and mouse cell lines. Toxicity of these siRNAs stems from targeting survival genes with C-rich 3'UTRs. The master tumor suppressor miRNA miR-34a-5p is toxic through such a G-rich 6mer seed and is upregulated in cells subjected to genotoxic stress. An analysis of all mature miRNAs suggests that during evolution most miRNAs evolved to avoid guanine at the 5' end of the 6mer seed sequence of the guide strand. In contrast, for certain tumor-suppressive miRNAs the guide strand contains a G-rich toxic 6mer seed, presumably to eliminate cancer cells.

Indexed as

AnimalsCell Line, TumorCell SurvivalDNA DamageGenes, EssentialGene TargetingGuanineHumansMiceMicroRNAsNeoplasmsRNA, Small InterferingUntranslated RegionsGuanineMicroRNAsRNA, Small InterferingUntranslated Regions

Identifiers

PMID30374110
PMCPMC6206098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.